Centauri Therapeutics
2014
FOUNDED
PRIVATE
STATUS
1-10
EMPLOYEES
Accelerator/Inc
LATEST DEAL TYPE
$1.22M
LATEST DEAL AMOUNT
5
INVESTORS
Description
Operator of biotechnology company intended to discover and develop novel molecules targeting life threatening diseases. The company's biotechnology service uses alphamer technology in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infections, enabling doctors to treat infectious diseases.
Website
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
- Discovery Park
- Kent CT13 9ND
- England, United Kingdom
+44 01304 000000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Centauri Therapeutics’s full profile, request a free trial.
Centauri Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Accelerator/Incubator | 11-Sep-2017 | $1.22M | 00.00 | Completed | Startup | |
| 2. Seed Round | 09-Mar-2017 | 00.00 | 00.00 | Completed | Startup | |
| 1. Seed Round | 20-Feb-2017 | $1.5M | $1.5M | Completed | Startup |
Centauri Therapeutics Competitors (12)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| DNAtrix | Venture Capital-Backed | Houston, TX | 00 | 000.00 | 00000000000 | 000.00 |
| 0000000 | Venture Capital-Backed | Newhouse, United Kingdom | 0 | 000.00 | 0000000000 0 | 000.00 |
| 00000 | Venture Capital-Backed | Cambridge, United Kingdom | 000 | 00000 | 0000000000 0 | 00000 |
| 00000 00000 000000 | Venture Capital-Backed | Geneva, Switzerland | 000 | 00000 | 0000000000 0 | 00000 |
| 0000000 | Venture Capital-Backed | San Diego, CA | 00 | 00000 | 0000000000 0 | 00000 |
Centauri Therapeutics Investments (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 000000000 | 02-Mar-2016 | 00000 0000000 | 00000 | Biotechnology | 0000000 000000 00.0 |
| Altermune Technologies | 18-Jan-2016 | Buyout/LBO | Therapeutic Devices | 0000000 000000 00.0 |
Centauri Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Innovate UK | Government | 000 0000 | 000000 0 | |||
| NCL Technology Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Renaissance Capital Partners | Growth/Expansion | Minority | 000 0000 | 000000 0 | ||
| Animatrix Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Discovery Park | Other | Minority | 000 0000 | 000000 0 |
Centauri Therapeutics Executive Team (2)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Michael Westby Ph.D | Board Member & Chief Executive Officer | ||
| Stuart Lawson | Board Member & Chief Financial Officer |
Centauri Therapeutics Board Members (4)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Clive Dix Ph.D | Centauri Therapeutics | Chairman | 000 0000 | |
| Michael Westby Ph.D | Centauri Therapeutics | Board Member & Chief Executive Officer | 000 0000 | |
| Stuart Lawson | Self | Board Member & Chief Financial Officer | 000 0000 |
1 Former Board Member
You’re viewing 3 of 4 board members. Get the full list »